66 results
Page 3 of 4
6-K
z2nftn fukq5pf
14 May 20
Current report (foreign)
7:25am
6-K
EX-10.1
j96w 2fkl5adv6v
12 May 20
Current report (foreign)
12:04pm
424B5
vrp 3lewybs
12 May 20
Prospectus supplement for primary offering
12:02pm
6-K
EX-10.1
epae7cufja 9gk8wex54
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
424B5
kqp76jqg 7j
11 May 20
Prospectus supplement for primary offering
9:23am
6-K
EX-99.1
e1knuyhd1em 1hb
19 Mar 20
Current report (foreign)
7:25am
6-K
peyteo7ud83evtf
14 Nov 19
Current report (foreign)
7:01am
6-K
EX-99.2
jnc8ecsa2t
1 Nov 19
Current report (foreign)
4:15pm
6-K/A
u1vv580
29 Aug 19
Current report (foreign) (amended)
5:25pm
6-K
4iflt4fetz91 e65as
13 Aug 19
Current report (foreign)
7:00am
6-K
EX-10.1
q5hxvwnnjjyk8b 7sui
17 May 19
Current report (foreign)
5:20pm
6-K
EX-99.2
itwrdkc5x0xxish
15 Oct 18
Notice of Annual General Meeting of Shareholders
8:15am
6-K
EX-1.1
79jxoz70ell bml
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am
6-K
EX-99.1
p19vc pa56
20 Oct 17
VBL Therapeutics Announces Orphan Drug Designation for VB-111 In Europe
12:00am
20-F/A
EX-4.3
ucr9 44gk
11 Oct 17
Annual report (foreign) (amended)
12:00am